NeoPharm Co Ltd
KOSDAQ:092730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NeoPharm Co Ltd
Cost of Revenue
NeoPharm Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
Cost of Revenue
-₩45.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-17%
|
|
|
AmorePacific Corp
KRX:090430
|
Cost of Revenue
-₩1.2T
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Amorepacific Group
KRX:002790
|
Cost of Revenue
-₩1.2T
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Cosmax Inc
KRX:192820
|
Cost of Revenue
-₩2T
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-16%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Cost of Revenue
-₩3.2T
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Cost of Revenue
-₩1.9T
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-17%
|
|
NeoPharm Co Ltd
Glance View
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.
See Also
What is NeoPharm Co Ltd's Cost of Revenue?
Cost of Revenue
-45.8B
KRW
Based on the financial report for Dec 31, 2025, NeoPharm Co Ltd's Cost of Revenue amounts to -45.8B KRW.
What is NeoPharm Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-17%
Over the last year, the Cost of Revenue growth was -2%. The average annual Cost of Revenue growth rates for NeoPharm Co Ltd have been -20% over the past three years , -15% over the past five years , and -17% over the past ten years .
